Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deaths Associated with Emicizumab in Patients with Hemophilia A.

× No keyword cloud information.

8 in total

Review 1. Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A.

Authors: Benjamin J Samelson-Jones; Valder R Arruda
Journal: Front Immunol Date: 2020-04-28 Impact factor: 7.561

Review 2. Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A.

Authors: Georg Gelbenegger; Christian Schoergenhofer; Paul Knoebl; Bernd Jilma
Journal: Thromb Haemost Date: 2020-07-27 Impact factor: 5.249

3. Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database.

Authors: Steven W Pipe; Rebecca Kruse-Jarres; Johnny N Mahlangu; Glenn F Pierce; Flora Peyvandi; Peter Kuebler; Christian De Ford; Fabián Sanabria; Richard H Ko; Tiffany Chang; Charles R M Hay
Journal: J Thromb Haemost Date: 2021-01 Impact factor: 5.824

4. Design of an international investigator-initiated study on MOdern Treatment of Inhibitor-positiVe pATiEnts with haemophilia A (MOTIVATE).

Authors: Carmen Escuriola Ettingshausen; Robert F Sidonio
Journal: Ther Adv Hematol Date: 2021-09-23

Deaths Associated with Emicizumab in Patients with Hemophilia A.

Review 1. Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A.

Review 2. Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A.

3. Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database.

4. Design of an international investigator-initiated study on MOdern Treatment of Inhibitor-positiVe pATiEnts with haemophilia A (MOTIVATE).

5. Time is Blood: The Impact of Diagnostic Delays on Acquired Hemophilia A.

6. Adeno-associated virus-mediated expression of activated factor V (FVa) for hemophilia phenotypic correction.

Review 7. Bispecific Antibodies and Advances in Non-Gene Therapy Options in Hemophilia.

Review 8. Hemophilia therapy: the future has begun.